litlas
Log inCreate account

Mitchell L. Shiffman

Active 1990–2025

Also published as
MITCHELL L. SHIFFMAN
141
Papers
54,882
Citations
104
h-index
141
i10-index

Citations

Citations per year for Mitchell L. Shiffman1986: 2 citations1987: 1 citations1991: 2 citations1992: 2 citations1993: 5 citations1994: 2 citations1995: 7 citations1996: 14 citations1997: 8 citations1998: 31 citations1999: 72 citations2000: 158 citations2001: 191 citations2002: 360 citations2003: 378 citations2004: 454 citations2005: 492 citations2006: 520 citations2007: 479 citations2008: 466 citations2009: 415 citations2010: 512 citations2011: 453 citations2012: 448 citations2013: 389 citations2014: 393 citations2015: 380 citations2016: 336 citations2017: 271 citations2018: 246 citations2019: 765 citations2020: 886 citations2021: 946 citations2022: 745 citations2023: 574 citations2024: 804 citations2025: 486 citations2026: 21 citations1988–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,891 citing papers, 28.4% of this breakdownChina: 934 citing papers, 6.8% of this breakdownUnited Kingdom: 829 citing papers, 6.1% of this breakdownItaly: 814 citing papers, 5.9% of this breakdownGermany: 773 citing papers, 5.6% of this breakdownFrance: 712 citing papers, 5.2% of this breakdownSpain: 499 citing papers, 3.6% of this breakdownCanada: 497 citing papers, 3.6% of this breakdownJapan: 472 citing papers, 3.5% of this breakdownAustralia: 354 citing papers, 2.6% of this breakdownNetherlands: 271 citing papers, 2% of this breakdownSwitzerland: 269 citing papers, 2% of this breakdown
0%28.4%Other 24.7%

Institutions

Fields

  • Medicine90.3%
  • Biochemistry, Genetics and Molecular Biology4.8%
  • Immunology and Microbiology1.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Neuroscience0.4%
  • Agricultural and Biological Sciences0.3%
  • Other1.5%

Topics

  • Liver Disease Diagnosis and Treatment17.7%
  • Hepatitis C virus research11.8%
  • Hepatitis B Virus Studies6.5%
  • Liver Disease and Transplantation6.4%
  • Liver Diseases and Immunity3.8%
  • Diet, Metabolism, and Disease3.1%
  • Other50.7%

Coauthors

All papers

Open in search
  1. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    Authors: Frederik Nevens, Pietro Andreoné, G. Mazzella, Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost P.H. Drenth, Paul J. Pockros, Jarosław Reguła, Ulrich Beuers, Michael Trauner, David Jones, Annarosa Floreani, Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J. van Erpecum, Vı́ctor Vargas, Catherine Vincent, Gideon M. Hirschfield, Hemant Shah, Bettina E. Hansen, Keith D. Lindor, Hanns–Ulrich Marschall, Kris V. Kowdley, Roya Hooshmand-Rad, Tonya Marmon, Shawn Sheeron, Richard Pencek, Leigh MacConell, Mark Pruzanski, Д. А. Шапиро - New England Journal of Medicine 2016 cited by 1,108

  2. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    Authors: Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Kumar Sarin, Stephen H. Caldwell, Naim Alkhouri, Mitchell L. Shiffman, Marianne Camargo, Georgia Li, Kathryn Kersey, Catherine Jia, Yanni Zhu, C. Stephen Djedjos, G. Mani Subramanian, Robert P. Myers, Nadege Gunn, Aasim Sheikh, Quentin M. Anstee, Manuel Romero‐Gómez, Michael Trauner, Zachary Goodman, Eric Lawitz, Zobair M. Younossi, Adrián Gadano, Marcelo Martins, Peter Angus, John Bate, Mark Danta, Jacob George, Alexander Hodge, Nickolas Kontorinis, S.A. Roberts, Santosh Sanagapalli, Richard Skoien, Alexander Thompson, Amany Zekry, Rudolf Stauber, Michael Trauner, Christophe Moreno, Hendrik Reynaert, Len Verbeke, Mário Reis Álvares‐da‐Silva, Edison Roberto Parise, Cláudia P. Oliveira, Roberta Chaves Araújo, Ana de Lourdes Candolo Martinelli, Meredith A. Borman, Natasha Chandok, Magdy Elkhashab, Hughie F. Fraser, Kelly Kaita, Mang Ma, Paul Marotta, Alnoor Ramji, Edward Tam, Eric M. Yoshida, Mark G. Swain, Giada Sebastiani, Denis Petrunia, Armand Abergel, Rodolphe Anty, Marc Bourlière, Jérôme Boursier, Christophe Bureau, Laurent Castéra, François Habersetzer, Christophe Hézode, V. de Lédinghen, Vincent Leroy, V. Loustaud‐Ratti, Philippe Mathurin, Stanislas Pol, Fabien Zoulim, Holger Hinrichsen, Patrick Ingiliz, Frank Lammert, Michael Manns, Jörn M. Schattenberg, Ingolf Schiefke, Christian Trautwein, Stefan Zeuzem, Aric J. Hui, K Li, Vincent Wai‐Sun Wong, Subrat Kumar Acharya, Abhijit Chowdhury, Ajay Duseja, Dharmesh Kapoor, Shrikant Mukewar, Shiv Kumar Sarin, Samir Shah, S. Shalimar, Ajit Sood, BV Tantry, Ziv Ben‐Ari, Helena Katchman and 540 more - Journal of Hepatology 2020 cited by 466

  3. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

    Authors: Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Ulus Salih Akarca, Mário Reis Álvares‐da‐Silva, Pietro Andreoné, Marco Arrese, Christophe Corpechot, Sven Francque, Michael A. Heneghan, Pietro Invernizzi, David Jones, Frederik C. Kruger, Eric Lawitz, Marlyn J. Mayo, Mitchell L. Shiffman, Mark G. Swain, José Miguel Valera, Vı́ctor Vargas, John M. Vierling, Alejandra Villamil, Carol Addy, Julie Dietrich, Jean‐Michel Germain, Sarah Mazain, Dragutin Rafailovic, Bachirou Taddé, Benjamin F. Miller, Jianfen Shu, Claudia O. Zein, Jörn M. Schattenberg - New England Journal of Medicine 2023 cited by 263

  4. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

    Authors: Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski, Murray B. Resnick, Andrew H. Beck, Dora Ding, Catherine Jia, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Keyur Patel, Brian B. Borg, Reem Ghalib, Heidi Kabler, John Poulos, Ziad Younes, Magdy Elkhashab, Tarek Hassanein, Rajalakshmi Iyer, Peter Ruane, Mitchell L. Shiffman, Simone I. Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, for the ATLAS Investigators - Hepatology 2020 cited by 278

  5. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

    Authors: Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary E. Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell L. Shiffman, Arun J. Sanyal, Adam Allgood, Harold Shlevin, R. G. Horton, Eliezer Zomer, William Irish, Zachary Goodman, Stephen A. Harrison, Peter G. Traber, Manal F. Abdelmalek, Luis A. Balart, Brian B. Borg, Naga Chalasani, Michael Charlton, Hari S. Conjeevaram, Michael Fuchs, Reem Ghalib, Pierre Gholam, Dina Halegoua‐De Marzio, Stephen A. Harrison, Christopher Jue, Nyingi Kemmer, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Mazen Noureddin, Angelo H. Paredes, Mary E. Rinella, Don C. Rockey, Miguel Rodriguez, Raymond A. Rubin, Michael Ryan, Arun J. Sanyal, Andrew Scanga, Thomas Sepe, Mitchell L. Shiffman, Mitchell L. Shiffman, Brent Tetri, Paul J. Thuluvath, Dawn M. Torres, John M. Vierling, Julia Wattacheril, Amanda Weiland, Donald L. Zogg - Gastroenterology 2019 cited by 344

  6. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities

    Authors: Arun J. Sanyal, Carol Campbell–Sargent, Faridoddin Mirshahi, William B. Rizzo, Melissa J. Contos, Richard K. Sterling, Velimir A. Luketic, Mitchell L. Shiffman, John N. Clore - Gastroenterology 2001 cited by 2,075

  7. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

    Authors: Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, James F. Trotter, Robert Herring, Sergio Rojter, Zeid Kayali, Vincent Wai‐Sun Wong, Susan Greenbloom, Saumya Jayakumar, Mitchell L. Shiffman, B. Freilich, Eric Lawitz, Edward Gane, Eliza Harting, Jun Xu, Andrew N. Billin, Chuhan Chung, C. Stephen Djedjos, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Mary E. Rinella, Mazen Noureddin - Hepatology 2020 cited by 321

  8. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

    Authors: Stephen A. Harrison, Manal F. Abdelmalek, Stephen H. Caldwell, Mitchell L. Shiffman, Anna Mae Diehl, Reem Ghalib, Eric Lawitz, Don C. Rockey, Raul Aguilar Schall, Catherine Jia, B. Mccolgan, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Zobair M. Younossi, Vlad Ratziu, Andrew J. Muir, Nezam H. Afdhal, Zachary Goodman, Jaime Bosch, Arun J. Sanyal - Gastroenterology 2018 cited by 372

  9. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

    Authors: Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen H. Caldwell, Mitchell L. Shiffman, Raul Aguilar Schall, Catherine Jia, B. Mccolgan, C. Stephen Djedjos, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Zobair M. Younossi, Andrew J. Muir, Nezam H. Afdhal, Jaime Bosch, Zachary Goodman - Hepatology 2019 cited by 389

  10. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

    Authors: Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew J. Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Georgia Li, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Christopher L. Bowlus, Kris V. Kowdley - Hepatology 2019 cited by 259

  11. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

    Authors: Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris V. Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreoné, Stuart C. Gordon, Christopher L. Bowlus, Eric Lawitz, Richard Aspinall, Daniel S. Pratt, K. L. Raikhelson, M.S. González-Huezo, Michael A. Heneghan, Sook‐Hyang Jeong, Alma Laura Ladrón De Guevara, Marlyn J. Mayo, George Ν. Dalekos, Joost P.H. Drenth, Ewa Janczewska, Barbara Leggett, Frederik Nevens, Vı́ctor Vargas, Eli Zuckerman, Christophe Corpechot, E Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak Trivedi, Lisa Forman, David E.J. Jones, Stephen Ryder, Mark G. Swain, Alexandra Steinberg, Pol Boudes, Yun‐Jung Choi, Charles A. McWherter, ENHANCE Study Group* - Hepatology 2023 cited by 113

  12. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

    Authors: Andrew J. Muir, Cynthia Levy, Harry L.A. Janssen, Aldo J. Montaño‐Loza, Mitchell L. Shiffman, Stephen H. Caldwell, Velimir A. Luketic, Dora Ding, Catherine Jia, B. Mccolgan, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Michael P. Manns, Roger W. Chapman, Nezam H. Afdhal, Zachary Goodman, Bertus Eksteen, Christopher L. Bowlus, for the GS‐US‐321‐0102 Investigators - Hepatology 2018 cited by 193

  13. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

    Authors: Quentin M. Anstee, Eric Lawitz, Naim Alkhouri, Vincent Wai‐Sun Wong, Manuel Romero‐Gómez, Takeshi Okanoue, Michael Trauner, Kathryn Kersey, Georgia Li, Ling Han, Catherine Jia, Lulu Wang, Guang Chen, G. Mani Subramanian, Robert P. Myers, C. Stephen Djedjos, Anita Kohli, Natalie Bzowej, Ziad Younes, Shiv Kumar Sarin, Mitchell L. Shiffman, Stephen A. Harrison, Nezam H. Afdhal, Zachary Goodman, Zobair M. Younossi - Hepatology 2019 cited by 266

  14. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

    Authors: David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark Jonas, Andreas E. Kremer, George Mells, Peter Buggisch, B. Freilich, Cynthia Levy, John M. Vierling, David Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. Smith, Yun‐Jung Choi, Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 186

  15. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values

    Authors: P MOFRAD, Melissa J. Contos, Mahmadul Haque, Carol Sargeant, Robert A. Fisher, Velimir A. Luketic, Richard K. Sterling, Mitchell L. Shiffman, Richard T. Stravitz, Arun J. Sanyal - Hepatology 2003 cited by 1,198

  16. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

    Authors: Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustı́n Albillos, James M. Robinson, David Hagerty, Jean L. Chan, Arun J. Sanyal, Manal F. Abdelmalek, K.R. Bhamidimarri, Brian B. Borg, Stephen H. Caldwell, Jonathan M. Fenkel, B. Freilich, Michael Fuchs, Marwan Ghabril, R. Ghalib, Stevan A. Gonzalez, Sonya G. Gordon, Bilal Hameed, Stephen A. Harrison, Zeid Kayali, Nyingi Kemmer, Kevin Korenblat, Ming‐Zong Lai, Charles Landis, E.J. Lawitz, William M. Lee, Steven D. Lidofsky, Edward Mena, Mazen Noureddin, Angelo H. Paredes, Nikolaos Pyrsopoulos, K. Rajender Reddy, M. Rinella, Don C. Rockey, Manuel Rodríguez, Michele B. Ryan, Souvik Sarkar, Sanjaya K. Satapathy, Andrew Scanga, Mitchell L. Shiffman, Mohammad Shadab Siddiqui, Douglas A. Simonetto, Wing‐Kin Syn, Paul J. Thuluvath, Ramesh Vemulapalli, John M. Vierling, Ziad Younes, Agustı́n Albillos, Juan Arenas Ruiz-Tapiador, Salvador Augustín, José Luís Calleja, J. Crespo Garcia, L. García Buey, Juan Carlos García‐Pagán, Càndid Villanueva, C. Bureau, N. Carbonell, Valériane Leroy, Pierre‐Emmanuel Rautou, HS Heinzow, Ingolf Schiefke, Alexander Zipprich, Annalisa Berzigotti, Beat Muellhaupt - Journal of Hepatology 2019 cited by 156

  17. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

    Authors: Christopher L. Bowlus, Michael Galambos, Richard Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo, Paul J. Thuluvath, Cynthia Levy, Mark G. Swain, Guy Neff, David Sheridan, Carmen Stanca, Christoph P. Berg, Aparna Goel, Mitchell L. Shiffman, John M. Vierling, Pol Boudes, Alexandra Steinberg, Yun‐Jung Choi, Charles A. McWherter - Journal of Hepatology 2022 cited by 79

  18. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

    Authors: Michael Trauner, Frederik Nevens, Mitchell L. Shiffman, Joost P.H. Drenth, Christopher L. Bowlus, Vı́ctor Vargas, Pietro Andreoné, Gideon M. Hirschfield, Richard Pencek, Elizabeth Smoot Malecha, Leigh MacConell, Д. А. Шапиро - ˜The œLancet. Gastroenterology & hepatology 2019 cited by 176

  19. Diagnosis and Management of Primary Biliary Cholangitis

    Authors: Zobair M. Younossi, David Bernstein, Mitchell L. Shiffman, Paul Y. Kwo, W. Ray Kim, Kris V. Kowdley, Ira M. Jacobson - The American Journal of Gastroenterology 2018 cited by 209

  20. Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial

    Authors: Leonard B. Seeff, Gregory T. Everson, Timothy R. Morgan, Teresa M. Curto, William M. Lee, Marc G. Ghany, Mitchell L. Shiffman, Robert J. Fontana, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Jules L. Dienstag - Clinical Gastroenterology and Hepatology 2010 cited by 466

  21. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

    Authors: Patrick Marcellin, E. Jenny Heathcote, Marı́a Buti, Ed Gane, Robert A. de Man, Zahary Krastev, G. Germanidis, Sam S. Lee, Robert Flisiak, Kelly Kaita, Michael P. Manns, Iskren Kotzev, К. Tchernev, Peter Buggisch, Frank Weilert, Oya Ovung Kurdas, Mitchell L. Shiffman, Huy N. Trinh, M. Kay Washington, J. Sorbel, Jane Anderson, Andrea Snow‐Lampart, Elsa Mondou, Joe Quinn, Franck Rousseau - New England Journal of Medicine 2008 cited by 1,179

  22. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C†

    Authors: Arun J. Sanyal, Colin Banas, Carol Sargeant, Velimir A. Luketic, Richard K. Sterling, Richard T. Stravitz, Mitchell L. Shiffman, Douglas M. Heuman, Adrian Coterrell, Robert A. Fisher, Melissa J. Contos, A. Scott Mills - Hepatology 2006 cited by 517

  23. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations

    Authors: Zobair M. Younossi, Mazen Noureddin, David Bernstein, Paul Y. Kwo, Mark W. Russo, Mitchell L. Shiffman, Ziad Younes, Manal F. Abdelmalek - The American Journal of Gastroenterology 2020 cited by 104

  24. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

    Authors: Catherine Frenette, Zeid Kayali, Edward Mena, Parvez Mantry, Kathryn Jean Lucas, Guy Neff, Miguel Rodriguez, Paul J. Thuluvath, Ethan M. Weinberg, Bal Raj Bhandari, J. E. M. Robinson, Nicole M. Wedick, Jean L. Chan, David Hagerty, Kris V. Kowdley, Kathleen E. Corey, David Bernstein, Mazen Noureddin, Nyingi Kemmer, Andrew S. deLemos, Nikolaos Pyrsopoulos, William Lee, Marwan Ghabril, Andrew Scanga, Mark McKenzie, Eric Lawitz, Viviana Figueroa-Diaz, Douglas A. Simonetto, R. Todd Frederick, Kimberly Brown, George Therapondos, Aasim Sheikh, Danielle Brandman, Lance L. Stein, Victor Ankoma‐Sey, Kalyan Ram Bhamidimarri, Charles Landis, Brett E. Fortune, Hugo E. Vargas, Manal F. Abdelmalek, B. Freilich, Don C. Rockey, John M. Vierling, H. Tatum, Michael P. Curry, Mitchell L. Shiffman, Kiran Bambha, Reem Ghalib, Amy Stratton, Nadeem Anwar, Stephen H. Caldwell, Ayman Koteish, Mohammad Siddiqui, Sammy Saab, Nikunj Shah, Anita Kohli, Mary E. Rinella, Souvik Sarkar, Dawn M. Torres, Elizabeth C. Verna, Ravi Ravendhran, Justin Reynolds, Ray Thomason, Ray Kim, Fernando E. Membreno, Simona Jakab, Stevan A. Gonzalez, Andrew P. Keaveny, Jen‐Jung Pan, Satinder Gill, Jonathan Huang, James Strobel, Amanda Wieland, Giuseppe Morelli, Thomas Amankonah, Marina Roytman, W Schmidt, Gary A. Abrams, Bhaktasharan Patel - Journal of Hepatology 2020 cited by 61